×
About 1,863 results

ALLMedicine™ Chordoma Center

Research & Reviews  681 results

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
https://clinicaltrials.gov/ct2/show/NCT00001163

Jun 24th, 2022 - Background: Persons may be prone to develop cancer for a variety of reasons including: inherited predisposition benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors, immune deficiency, or...

Children and Adults With Chordoma
https://clinicaltrials.gov/ct2/show/NCT03910465

Jun 24th, 2022 - Background: Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordoma...

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
https://clinicaltrials.gov/ct2/show/NCT01200680

Jun 24th, 2022 - Synopsis Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than fema...

Long-term outcomes of high dose carbon-ion radiation therapy for unresectable upper cer...
https://doi.org/10.1002/hed.27127
Head & Neck; Aoki S, Koto M et. al.

Jun 24th, 2022 - Chordoma is a rare, locally invasive neoplasm of the axial skeleton. Complete resection is often difficult, especially for the upper-cervical (C1-2) spine. We evaluated the efficacy and safety of carbon-ion radiotherapy (CIRT) for unresectable C1-...

New molecular entities of soft tissue and bone tumors.
https://doi.org/10.1097/CCO.0000000000000844
Current Opinion in Oncology; Lam SW, Silva TM et. al.

Jun 23rd, 2022 - The advances of molecular techniques have led to the refinement of the classification of mesenchymal tumors, leading to newly introduced entities in the recently published fifth edition of the WHO Classification of Soft Tissue and Bone Tumors, whi...

see more →

Guidelines  1 results

Bone cancer.
https://doi.org/10.6004/jnccn.2013.0088
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 8th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

see more →

Clinicaltrials.gov  38 results

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
https://clinicaltrials.gov/ct2/show/NCT00001163

Jun 24th, 2022 - Background: Persons may be prone to develop cancer for a variety of reasons including: inherited predisposition benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors, immune deficiency, or...

Children and Adults With Chordoma
https://clinicaltrials.gov/ct2/show/NCT03910465

Jun 24th, 2022 - Background: Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordoma...

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
https://clinicaltrials.gov/ct2/show/NCT01200680

Jun 24th, 2022 - Synopsis Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than fema...

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
https://clinicaltrials.gov/ct2/show/NCT04246671

Jun 10th, 2022 - A Phase 1 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in patients with advanced brachyury and/or HER2- expressing cancer. The study will be completed in 2 stages. In Stage 1 patients will be enrolled and treated accord...

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
https://clinicaltrials.gov/ct2/show/NCT02989636

Jun 9th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety profile of nivolumab alone and nivolumab in combination with stereotactic radiosurgery to treat patients with recurrent or advanced chordoma. SECONDARY OBJECTIVES: I. To evaluate toxicity and tolerabilit...

see more →

News  18 results

Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-tazemetostat-in-pediatric-patients-with-ini1negative-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients w...

Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors
https://www.onclive.com/view/dr-chi-discusses-pediatric-atypical-teratoid-rhabdoid-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors (ATRTs). A...

Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors
https://www.onclive.com/view/tazemetostat-shows-antitumor-activity-in-ini1negative-pediatric-tumors

Dec 20th, 2020 - Susan N. Chi, MD Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors, according to results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.1 In the dose-...

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-study-of-tazemetostat-in-children-with-ini1negative-tumors

Dec 20th, 2020 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children...

Lead Investigator Discusses Tazemetostat Data in INI1-Negative Pediatric Tumors
https://www.onclive.com/view/lead-investigator-discusses-tazemetostat-data-in-ini1negative-pediatric-tumors

Dec 4th, 2020 - Susan N. Chi, MD Tazemetostat showed promising antitumor activity in pediatric patients with INI1-negative rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma tumors, according to findings presented at the 2018 ASPHO Conference. ...

see more →

Patient Education  7 results see all →